Maiwei Biotech (688062.SH): Application for clinical trial of injection 6MW5311 approved by FDA

Maiwei Biotechnology (688062.SH) announced that the company has recently received a "Notice of Continuation of Clinical Research" issued by the Food and Drug Administration (FDA) of the United States. The clinical trial application for injection use of 6MW5311 in the treatment of hematologic malignancies (Acute Myeloid Leukemia (AML), Chronic Myelomonocytic Leukemia (CMML), and Multiple Myeloma (MM)) has officially obtained FDA approval. In addition, the clinical trial application for 6MW5311 has been accepted by the National Medical Products Administration. 6MW5311 is the world's first targeted LILRB4/CD3 TCE innovative drug to be approved for clinical trials.